Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening Units

A new multivalent vaccine (DIVENCE<sup>®</sup>), containing live gE/tk double-gene-deleted BoHV-1, live-attenuated BRSV, inactivated PI3, and BVDV-1, and BVDV-2 recombinant proteins, has been designed to protect cattle against the main viral pathogens associated with bovine respiratory d...

Full description

Saved in:
Bibliographic Details
Main Authors: Mariona Tapiolas, Marta Gibert, Carlos Montbrau, Ester Taberner, Marina Solé, Héctor Santo Tomás, Ainhoa Puig, Ricard March
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/12/11/1233
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846152305626316800
author Mariona Tapiolas
Marta Gibert
Carlos Montbrau
Ester Taberner
Marina Solé
Héctor Santo Tomás
Ainhoa Puig
Ricard March
author_facet Mariona Tapiolas
Marta Gibert
Carlos Montbrau
Ester Taberner
Marina Solé
Héctor Santo Tomás
Ainhoa Puig
Ricard March
author_sort Mariona Tapiolas
collection DOAJ
description A new multivalent vaccine (DIVENCE<sup>®</sup>), containing live gE/tk double-gene-deleted BoHV-1, live-attenuated BRSV, inactivated PI3, and BVDV-1, and BVDV-2 recombinant proteins, has been designed to protect cattle against the main viral pathogens associated with bovine respiratory disease (BRD). The aim of this study was to demonstrate the efficacy of DIVENCE<sup>®</sup> against BRD in field conditions. A total of 360 animals from three different farms were included in this study. Calves were randomly distributed to the vaccinated (<i>n</i> = 183; DIVENCE<sup>®</sup>) or control (<i>n</i> = 177; phosphate-buffered saline solution) group. All animals received two intramuscular doses (2 mL/dose) three weeks apart of the corresponding product. The entire fattening period (approximately 9 months) was monitored to assess the incidence, severity, and morbidity of BRD as well as administered treatments and growth performance. During this study, a BRSV outbreak was reported in one farm, where vaccinated animals had significantly (<i>p</i> < 0.02) lower morbidity (20.4%) and severity (score of 1.70) compared to the control group (53.70% and score of 2.11). Overall, vaccinated animals had a significantly lower number of cases (<i>p</i> < 0.001; 0.36 vs. 0.64 cases/calf), lower morbidity (<i>p</i> < 0.004; 26.78% vs. 41.24%), and lower antimicrobial treatments (<i>p</i> = 0.01; 33.3% vs. 57.4%) than control animals. Vaccinated animals presented significantly (<i>p</i> = 0.01) higher carcass weight than controls (6.58 kg). Vaccination with DIVENCE<sup>®</sup> at the beginning of the fattening period decreased the incidence and morbidity of BRD following a BRSV outbreak. Additionally, the overall incidence and morbidity of BRD throughout the entire fattening period were reduced across farms. Thus, DIVENCE<sup>®</sup> can improve economic outcomes in fattening units by reducing antibiotic treatments and enhancing performance.
format Article
id doaj-art-ea9f25ec9207457c87473ace3b2cd85c
institution Kabale University
issn 2076-393X
language English
publishDate 2024-10-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj-art-ea9f25ec9207457c87473ace3b2cd85c2024-11-26T18:24:32ZengMDPI AGVaccines2076-393X2024-10-011211123310.3390/vaccines12111233Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening UnitsMariona Tapiolas0Marta Gibert1Carlos Montbrau2Ester Taberner3Marina Solé4Héctor Santo Tomás5Ainhoa Puig6Ricard March7Hipra Scientific S.L.U., Avda. La Selva 135, 17170 Amer, SpainHipra Scientific S.L.U., Avda. La Selva 135, 17170 Amer, SpainHipra Scientific S.L.U., Avda. La Selva 135, 17170 Amer, SpainHipra Scientific S.L.U., Avda. La Selva 135, 17170 Amer, SpainHIPRA S.A., Avinguda La Selva 135, 1710 Amer, SpainHIPRA S.A., Avinguda La Selva 135, 1710 Amer, SpainHipra Scientific S.L.U., Avda. La Selva 135, 17170 Amer, SpainHipra Scientific S.L.U., Avda. La Selva 135, 17170 Amer, SpainA new multivalent vaccine (DIVENCE<sup>®</sup>), containing live gE/tk double-gene-deleted BoHV-1, live-attenuated BRSV, inactivated PI3, and BVDV-1, and BVDV-2 recombinant proteins, has been designed to protect cattle against the main viral pathogens associated with bovine respiratory disease (BRD). The aim of this study was to demonstrate the efficacy of DIVENCE<sup>®</sup> against BRD in field conditions. A total of 360 animals from three different farms were included in this study. Calves were randomly distributed to the vaccinated (<i>n</i> = 183; DIVENCE<sup>®</sup>) or control (<i>n</i> = 177; phosphate-buffered saline solution) group. All animals received two intramuscular doses (2 mL/dose) three weeks apart of the corresponding product. The entire fattening period (approximately 9 months) was monitored to assess the incidence, severity, and morbidity of BRD as well as administered treatments and growth performance. During this study, a BRSV outbreak was reported in one farm, where vaccinated animals had significantly (<i>p</i> < 0.02) lower morbidity (20.4%) and severity (score of 1.70) compared to the control group (53.70% and score of 2.11). Overall, vaccinated animals had a significantly lower number of cases (<i>p</i> < 0.001; 0.36 vs. 0.64 cases/calf), lower morbidity (<i>p</i> < 0.004; 26.78% vs. 41.24%), and lower antimicrobial treatments (<i>p</i> = 0.01; 33.3% vs. 57.4%) than control animals. Vaccinated animals presented significantly (<i>p</i> = 0.01) higher carcass weight than controls (6.58 kg). Vaccination with DIVENCE<sup>®</sup> at the beginning of the fattening period decreased the incidence and morbidity of BRD following a BRSV outbreak. Additionally, the overall incidence and morbidity of BRD throughout the entire fattening period were reduced across farms. Thus, DIVENCE<sup>®</sup> can improve economic outcomes in fattening units by reducing antibiotic treatments and enhancing performance.https://www.mdpi.com/2076-393X/12/11/1233bovine respiratory disease (BRD)morbidityincidenceantimicrobialsfield conditionsperformance
spellingShingle Mariona Tapiolas
Marta Gibert
Carlos Montbrau
Ester Taberner
Marina Solé
Héctor Santo Tomás
Ainhoa Puig
Ricard March
Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening Units
Vaccines
bovine respiratory disease (BRD)
morbidity
incidence
antimicrobials
field conditions
performance
title Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening Units
title_full Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening Units
title_fullStr Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening Units
title_full_unstemmed Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening Units
title_short Efficacy of a New Multivalent Vaccine for the Control of Bovine Respiratory Disease (BRD) in a Randomized Clinical Trial in Commercial Fattening Units
title_sort efficacy of a new multivalent vaccine for the control of bovine respiratory disease brd in a randomized clinical trial in commercial fattening units
topic bovine respiratory disease (BRD)
morbidity
incidence
antimicrobials
field conditions
performance
url https://www.mdpi.com/2076-393X/12/11/1233
work_keys_str_mv AT marionatapiolas efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits
AT martagibert efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits
AT carlosmontbrau efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits
AT estertaberner efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits
AT marinasole efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits
AT hectorsantotomas efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits
AT ainhoapuig efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits
AT ricardmarch efficacyofanewmultivalentvaccineforthecontrolofbovinerespiratorydiseasebrdinarandomizedclinicaltrialincommercialfatteningunits